ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. reduced its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 52.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 70,400 shares of the biopharmaceutical company’s stock after selling 78,000 shares during the period. Privium Fund Management B.V.’s holdings in ACADIA Pharmaceuticals were worth $1,502,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Maryland State Retirement & Pension System increased its stake in ACADIA Pharmaceuticals by 1.3% during the 2nd quarter. Maryland State Retirement & Pension System now owns 36,397 shares of the biopharmaceutical company’s stock valued at $785,000 after purchasing an additional 476 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of ACADIA Pharmaceuticals by 0.7% during the second quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock worth $1,964,000 after buying an additional 626 shares during the period. GAMMA Investing LLC grew its holdings in shares of ACADIA Pharmaceuticals by 25.8% during the third quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 690 shares during the last quarter. Geneos Wealth Management Inc. increased its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 756 shares during the period. Finally, Yousif Capital Management LLC increased its position in shares of ACADIA Pharmaceuticals by 1.7% in the 2nd quarter. Yousif Capital Management LLC now owns 46,773 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 790 shares during the period. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Stock Down 2.2%

NASDAQ:ACAD opened at $25.13 on Friday. ACADIA Pharmaceuticals Inc. has a 52 week low of $13.40 and a 52 week high of $28.35. The stock’s 50-day moving average price is $26.49 and its 200-day moving average price is $24.39. The stock has a market capitalization of $4.25 billion, a PE ratio of 16.21, a price-to-earnings-growth ratio of 6.22 and a beta of 0.68.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.28. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.The company had revenue of $278.63 million for the quarter, compared to the consensus estimate of $276.52 million. During the same quarter in the prior year, the business posted $0.20 earnings per share. ACADIA Pharmaceuticals’s revenue for the quarter was up 11.3% on a year-over-year basis. Sell-side analysts expect that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 10,262 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total transaction of $243,106.78. Following the completion of the transaction, the executive vice president directly owned 53,338 shares in the company, valued at approximately $1,263,577.22. This represents a 16.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James M. Daly sold 30,000 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $22.37, for a total transaction of $671,100.00. Following the completion of the sale, the director owned 4,041 shares in the company, valued at approximately $90,397.17. This trade represents a 88.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 44,346 shares of company stock worth $1,010,957 in the last quarter. Corporate insiders own 26.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ACAD shares. JPMorgan Chase & Co. dropped their price target on ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Monday, November 17th. Royal Bank Of Canada decreased their target price on ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. UBS Group increased their price target on shares of ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright raised their target price on shares of ACADIA Pharmaceuticals from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.16.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.